4-(3-cyanophenyl)-3-thiosemicarbazide | 387363-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-cyanophenyl)-3-thiosemicarbazide
• 英文别名: 1-Amino-3-(3-cyanophenyl)thiourea
• CAS: 387363-40-8
• 化学式: C₈H₈N₄S
• 分子量: 192.244
• InChiKey: YFKHSXXWOSKROA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-cyanophenyl)-3-thiosemicarbazide 、 间苯三酚甲醛 以 乙醇 为溶剂， 反应 4.0h， 以70%的产率得到1-(3-cyanophenyl)-3-[(2,4,6-trihydroxyphenyl)methylidene]aminothiourea
  参考文献：
  名称：

  羟基取代的苯甲醛衍生的硫代半氨基甲酮，Hy和二硫代氨基甲酸酯对黄嘌呤氧化酶的抑制作用

  摘要：

  非嘌呤黄嘌呤氧化还原酶（XOR）抑制剂是嘌呤类似物别嘌呤醇的重要替代品，别嘌呤醇仍然是治疗与血液中尿酸水平升高有关的疾病的最广泛使用的药物。通过将单，二和三羟基苯甲醛与芳族硫代氨基脲，芳基酰肼和二硫代氨基甲酸酯缩合，合成了三组结构相关的席夫碱，表征并测试了其XOR抑制活性。发现苯甲醛成分对位的羟基取代具有较高的抑制活性。酰基的效力一般不如含硫羰基的席夫碱。内的缩氨基硫脲系列，氯和氰基的取代基对在相同的分析条件下测得，硫代氨基脲单元的位置进一步提高了活性，其效力比基准别嘌呤醇的效力高约四倍。为了说明席夫碱直接与酶活性位点上的钼中心结合的潜力，将每个抑制剂系列的一个代表性实例（H 2 L）与一个顺式-二氧钼（VI）单元配位。 ，以及生成的络合物[MoO 2（L）MeOH]的结构表征。然而，随后的稳态动力学研究表明，混合型抑制作用类似于已知在远离Mo中心的酶的底物进入通道内结合的抑制剂所观察到的

  DOI：

  10.1002/cmdc.201100054
• 作为产物：
  描述：

  3-氰基-苯硫代异氰酸酯 在 一水合肼 作用下， 生成 4-(3-cyanophenyl)-3-thiosemicarbazide
  参考文献：
  名称：

  羟基取代的苯甲醛衍生的硫代半氨基甲酮，Hy和二硫代氨基甲酸酯对黄嘌呤氧化酶的抑制作用

  摘要：

  非嘌呤黄嘌呤氧化还原酶（XOR）抑制剂是嘌呤类似物别嘌呤醇的重要替代品，别嘌呤醇仍然是治疗与血液中尿酸水平升高有关的疾病的最广泛使用的药物。通过将单，二和三羟基苯甲醛与芳族硫代氨基脲，芳基酰肼和二硫代氨基甲酸酯缩合，合成了三组结构相关的席夫碱，表征并测试了其XOR抑制活性。发现苯甲醛成分对位的羟基取代具有较高的抑制活性。酰基的效力一般不如含硫羰基的席夫碱。内的缩氨基硫脲系列，氯和氰基的取代基对在相同的分析条件下测得，硫代氨基脲单元的位置进一步提高了活性，其效力比基准别嘌呤醇的效力高约四倍。为了说明席夫碱直接与酶活性位点上的钼中心结合的潜力，将每个抑制剂系列的一个代表性实例（H 2 L）与一个顺式-二氧钼（VI）单元配位。 ，以及生成的络合物[MoO 2（L）MeOH]的结构表征。然而，随后的稳态动力学研究表明，混合型抑制作用类似于已知在远离Mo中心的酶的底物进入通道内结合的抑制剂所观察到的

  DOI：

  10.1002/cmdc.201100054

文献信息

• Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties
  作者：Silvia Serra、Laurence Moineaux、Christelle Vancraeynest、Bernard Masereel、Johan Wouters、Lionel Pochet、Raphaël Frédérick

  DOI：10.1016/j.ejmech.2014.05.044

  日期：2014.7

  of the indoleamine 2,3-dioxygenase (IDO), a promising therapeutic target for anticancer immunotherapy, a series of 32 phenylthiosemicarbazide derivatives was prepared and their IDO inhibition evaluated. Our study demonstrated that among these derivatives, compound 14 characterized with a 4-cyanophenyl group on the thiosemicarbazide was the more potent IDO inhibitor in this series being endowed with an

  为了探索硫代氨基脲化合物对抑制吲哚胺2,3-二加氧酶（IDO）的兴趣，IDA是抗癌免疫疗法的有希望的治疗靶标，制备了一系列32种苯基硫代氨基脲衍生物并评估了它们对IDO的抑制作用。我们的研究表明，在这些衍生物中，在硫代氨基脲上具有4-氰基苯基特征的化合物14是该系列中最有效的IDO抑制剂，具有IC 50为1.2μM。所描绘的SAR显示，相对于苯硫代氨基脲而言，在3-位和4-位的取代非常有前景，而在2-位的取代总是导致效力较低或无活性的衍生物。实际上，该研究突出了一种新颖有趣的IDO抑制支架，以进一步发展。
• Synthesis, Cytotoxic and Phytotoxic Effects of Some New N4-Aryl Substituted Isatin-3-thiosemicarbazones
  作者：Humayun Pervez、Muhammad Ramzan、Muhammad Yaqub、Khalid Mohammed Khan

  DOI：10.2174/157018011795514159

  日期：2011.6.1

  A series of N4-aryl substituted isatin-3-thiosemicarbazones was prepared by the reaction of isatin with an appropriate thiosemicarbazide in ethanol containing a few drops of acetic acid. The newly synthesized compounds were characterized by means of their analytical (CHN) and spectral (IR, 1H-NMR, EIMS) data, and evaluated for their cytotoxicity and phytotoxicity potential. Eleven out of thirteen compounds tested proved to be active in the brine-shrimp lethality bioassay exhibiting significant cytotoxic activity with LD50 values ranging from 1.75x10-5M to 1.91x10-4M. In phytotoxicity assay, all the synthesized compounds, regardless of the nature of aryl substituents, demonstrated weak to moderate (5-30%) plant growth inhibition at the highest tested concentration (500 μg/mL).

  一系列N4-芳基取代的异吲哚-3-硫半卡巴脒通过异吲哚与适当的硫脲在含有几滴醋酸的乙醇中反应制备。新合成的化合物通过其分析（CHN）和谱学（IR、1H-NMR、EIMS）数据进行表征，并评估了它们的细胞毒性和植物毒性潜力。在十三种测试的化合物中，有十一种在卤虫 lethality 生物测定中表现出显著的细胞毒活性，LD50值范围从1.75x10-5M到1.91x10-4M。在植物毒性测定中，所有合成的化合物，无论芳基取代基的性质如何，在最高测试浓度（500 μg/mL）下均表现出轻微至中等（5-30%）的植物生长抑制作用。
• Synthesis, bioactivity and binding energy calculations of novel 3-ethoxysalicylaldehyde based thiosemicarbazone derivatives
  作者：Muhammad Ishaq、Parham Taslimi、Zahid Shafiq、Samra Khan、Ramin Ekhteiari Salmas、Mohammad Mahdi Zangeneh、Aamer Saeed、Akram Zangeneh、Nastaran Sadeghian、Asnuzilawati Asari、Habsah Mohamad

  DOI：10.1016/j.bioorg.2020.103924

  日期：2020.7

  In recent decade, the entrance of α-N-heterocyclic thiosemicarbazones derivates (Triapne, COTI-2 and DpC) in clinical trials for cancer and HIV-1 has vastly increased the interests of medicinal chemists towards this class of organic compounds. In the given study, a series of eighteen new (3a-r) 3-ethoxy salicylaldehyde-based thiosemicarbazones (TSC), bearing aryl and cycloalkyl substituents, were synthesized and assayed for their pharmacological potential against carbonic anhydrases (hCA I and hCA II), cholinesterases (AChE and BChE) and α-glycosidase. The hCA I isoform was inhibited by these novel 3-ethoxysalicylaldehyde thiosemicarbazone derivatives (3a-r) in low nanomolar levels, the Ki of which differed between 144.18 ± 26.74 and 454.92 ± 48.32 nM. Against the physiologically dominant isoform hCA II, the novel compounds demonstrated Kis varying from 110.54 ± 14.05 to 444.12 ± 36.08 nM. Also, these novel derivatives (3a-r) effectively inhibited AChE, with Ki values in the range of 385.38 ± 45.03 to 983.04 ± 104.64 nM. For BChE was obtained with Ki values in the range of 400.21 ± 35.68 to 1003.02 ± 154.27 nM. For α-glycosidase the most effective Ki values of 3l, 3n, and 3q were with Ki values of 12.85 ± 1.05, 16.03 ± 2.84, and 19.16 ± 2.66 nM, respectively. Moreover, the synthesized TCSs were simulated using force field methods whereas the binding energies of the selected compounds were estimated using MM-GBSA method. The findings indicate the present novel 3-ethoxy salicylaldehyde-based thiosemicarbazones to be excellent hits for pharmaceutical applications.
• 5-Nitroisatin-derived thiosemicarbazones: potential antileishmanial agents
  作者：Humayun Pervez、Nazia Manzoor、Muhammad Yaqub、Khalid Mohammed Khan

  DOI：10.3109/14756366.2013.836641

  日期：2014.10.1

  A series of 29 previously reported N(4)-substituted 5-nitroisatin-3-thiosemicarbazones 2-30 has been screened for leishmanicidal potential. Compounds 2-4, 7, 8, 10-13, 15-19, 21, 23, 24, 26, 28 and 30 exhibited good to excellent antileishmanial activities with IC50 values ranging from 0.44 ± 0.02 to 32.38 ± 0.66 µg/mL. Of these, 5, 7, 19 and 28 proved to be the most active antileishmanial agents, displaying activities with IC50 values 1.78 ± 0.35, 0.44 ± 0.02, 1.91 ± 0.04 and 4.28 ± 0.75 µg/mL, respectively, which were even better than the standard drug, pentamidine (IC50 = 5.09 ± 0.04 µg/mL). This study presents the first example of exhibition of leishmanicidal potential by isatin-thiosemicarbazones and as such furnishes a solid basis for further research on these compounds to develop more potent antileishmanial agents.
• Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity
  作者：Kunal Kumar、Peter Man-Un Ung、Peng Wang、Hui Wang、Hailing Li、Mary K. Andrews、Andrew F. Stewart、Avner Schlessinger、Robert J. DeVita

  DOI：10.1016/j.ejmech.2018.08.007

  日期：2018.9

  The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurological disorders (Down syndrome, Alzheimer's disease), oncology, and diabetes (pancreatic beta-cell expansion). Current small molecule DYRK1A inhibitors are ATP-competitive inhibitors that bind to the kinase in an active conformation. As a result, these inhibitors are promiscuous, resulting in pharmacological side effects that limit their therapeutic applications. None are in clinical trials at this time. In order to identify a new DYRK1A inhibitor scaffold, we constructed a homology model of DYRK1A in an inactive, DFG-out conformation. Virtual screening of 2.2 million lead-like compounds from the ZINC database, followed by in vitro testing of selected 68 compounds revealed 8 hits representing 5 different chemical classes. We chose to focus on one of the hits from the computational screen, thiadiazine I which was found to inhibit DYRK1A with IC50 of 9.41 mu m (K-d = 7.3 mu M). Optimization of the hit compound 1, using structure-activity relationship (SAR) analysis and in vitro testing led to the identification of potent thiadiazine analogs with significantly improved binding as compared to the initial hit (K-d = 71-185 nM). Compound 3-5 induced human beta-cell proliferation at 5 mu M while showing selectivity for DYRK1A over DYRK1B and DYRK2 at 10 mu M. This newly developed DYRK1A inhibitor scaffold with unique kinase selectivity profiles has potential to be further optimized as novel therapeutics for diabetes. (C) 2018 Published by Elsevier Masson SAS.